INTERNATIONAL PATENT: JIANGSU HENGRUI PHARMACEUTICALS CO., LTD., 江苏恒瑞医药股份有限公司 FILES APPLICATION FOR "USE OF ANTI-HER3 ANTIBODY-DRUG CONJUGATE IN TREATING TUMORS AND METHOD FOR TREATING TUMORS USING ANTI-HER3 ANTIBODY-DRUG CONJUGATE"

Posted On: 2025-03-31

GENEVA, March 31 -- JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (No. 7 Kunlunshan Road, Economic And Technological Development ZoneLianyungang, Jiangsu 222047), 江苏恒瑞医药股份有限公司 (中国江苏省连云港市经济技术开发区昆仑山路7号) filed a patent application (PCT/CN2024/120021) for "USE OF ANTI-HER3 ANTIBODY-DRUG CONJUGATE IN TREATING TUMORS AND METHOD FOR TREATING TUMORS USING ANTI-HER3 ANTIBODY-DRUG CONJUGATE" on Sep 20, 2024. With publication no. WO/2025/061145, the details related to the patent application was published on Mar 27, 2025.

Notabl...

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

INTERNATIONAL PATENT: JIANGSU HENGRUI PHARMACEUTICALS CO., LTD., 江苏恒瑞医药股份有限公司 FILES APPLICATION FOR "USE OF ANTI-HER3 ANTIBODY-DRUG CONJUGATE IN TREATING TUMORS AND METHOD FOR TREATING TUMORS USING ANTI-HER3 ANTIBODY-DRUG CONJUGATE"